GCM
TNGX icon

Graham Capital Management’s Tango Therapeutics TNGX Stock Holding History

Graham Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,319
Closed -$455K – 1512
2025
Q4 		$455K Buy
+51,319
New +$442K 0.01% 657
2025
Q2 		– Sell
-116,498
Closed -$160K – 1623
2025
Q1 		$160K Buy
116,498
+81,694
+235% +$201K ﹤0.01% 1166
2024
Q4 		$108K Buy
+34,804
New +$162K ﹤0.01% 1147
2024
Q2 		– Sell
-24,405
Closed -$194K – 1367
2024
Q1 		$194K Buy
+24,405
New +$262K ﹤0.01% 904

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Graham Capital Management's TNGX Position: Q1 2026 in Review

Graham Capital Management sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 51,319 shares — an estimated $455K sold.

Graham Capital Management first reported a position in TNGX in Q1 2024 and held it in 4 quarters. The position peaked at $455K in Q4 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Graham Capital Management reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 51,319 Tango Therapeutics shares in Q1 2026, an estimated $455K.
  • Graham Capital Management first reported a position in Tango Therapeutics in Q1 2024 and held it in 4 quarters.
  • Graham Capital Management's Tango Therapeutics position peaked at $455K in Q4 2025.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.